Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given a consensus rating of “Hold” by the twenty-two research firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $106.20.

ZBH has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. UBS Group restated a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a report on Wednesday, February 11th. Barclays reduced their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research report on Thursday, February 12th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Finally, Weiss Ratings lowered shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 23rd.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently modified their holdings of the stock. Legacy Wealth Asset Management LLC lifted its holdings in shares of Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 106 shares during the last quarter. Global Retirement Partners LLC raised its position in Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 111 shares in the last quarter. Main Management ETF Advisors LLC raised its position in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after acquiring an additional 112 shares in the last quarter. Cullen Frost Bankers Inc. lifted its stake in Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the last quarter. Finally, Generali Asset Management SPA SGR grew its position in Zimmer Biomet by 0.9% in the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after acquiring an additional 122 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.1%

Shares of ZBH opened at $88.52 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $17.32 billion, a P/E ratio of 25.01, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58. The stock’s fifty day simple moving average is $92.02 and its 200 day simple moving average is $93.90. Zimmer Biomet has a twelve month low of $84.59 and a twelve month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.